Patents Examined by Jeanette Lieb
  • Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 9730978
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: August 15, 2017
    Assignees: Thc Regents of the University of California, Schepens Eye Research Institute
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Patent number: 9731046
    Abstract: The present invention provides a multi-compartment hydrogel, and a sulfated polysaccharide and at least two bioactive polypeptides capable of binding said sulfated polysaccharide, for use in repair or regeneration of a damaged tissue in a mammal. Also provided is a method for constructing the multi-compartment hydrogel. The present invention also provides a method for the repair or regeneration of a damaged tissue in a mammal, and a kit for constructing a multi-compartment hydrogel.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: August 15, 2017
    Assignee: Ben Gurion University of the Negev Research and Development Authority
    Inventors: Smadar Cohen, Tali Re'Em, Emil Ruvinov
  • Patent number: 9724423
    Abstract: The present invention relates to shear-thinning ?-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: August 8, 2017
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique
    Inventors: Vincent Forge, Carole Mathevon, Frédéric Pignon
  • Patent number: 9718768
    Abstract: The invention relates to a lock-release method to be applied to biomolecules, such as antibodies, to improve the purification, production, stability and storage of biomolecules. A biomolecule is covalently bound to a polymer support comprising a diketone group so that the biomolecule can be purified, produced and/or stored before being released from the support. The diketone group of the polymer support is a 1,3-ketoester, 1,3-ketothioester or 1,3-ketoamide is a group of Formula (1): R1 is an optionally substituted hydrocarbyl, perhalogenated hydrocarbyl, or a heterocyclyl group; Y is hydrogen, an optionally substituted hydrocarbyl, or a heterocyclyl group; X is —O, —NR2 or —S, wherein the free valence of —O, —NR2 or —S is bonded to the support optionally via a linker; and R2 is hydrogen, an optionally substituted hydrocarbyl, or a heterocyclyl group. The invention also relates to a polymer support comprising the diketone group.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: August 1, 2017
    Assignee: ADC Biotechnology Ltd.
    Inventor: David Evans
  • Patent number: 9713644
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 9708367
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 18, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • Patent number: 9708383
    Abstract: The invention relates to a derivative of a GLP-1 analog, which analog comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: HOOC—(CH2)x—CO—*??Chem. 1: HOOC—C6H4—O—(CH2)y—CO—*??Chem. 2: R2—C6H4—(CH2)z—CO—*,??Chem. 3: in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises *—NH—(CH2)2—(O—(CH2)2)k—O—(CH2)n—CO—*.??Chem. 4: wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 18, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Alice Ravn Madsen, Birgit Wieczorek, Jacob Kofoed, Jesper Lau, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Patrick William Garibay, Per Sauerberg, Thomas Kruse
  • Patent number: 9701713
    Abstract: Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: July 11, 2017
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Jonathan Mark Petrash, Niklaus Mueller
  • Patent number: 9700591
    Abstract: Provided herein is a method of treating weight loss in one or more companion animals or livestock. The method can provide administering a therapeutically effective amount of a capromorelin-containing composition to a companion animal or livestock in need thereof for a period of at least 30 days. Optionally, one or more flavoring agents or flavor-masking agents can be added to the capromorelin-containing composition to enhance or mask the flavoring of the composition for the companion animal or livestock.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: July 11, 2017
    Assignee: Aratana Therapeutics, Inc.
    Inventors: Linda Rhodes, Marie-Paul Lachaud, Bill Zollers, Ernst Heinen
  • Patent number: 9700631
    Abstract: Described herein are low protein concentration gelling compositions comprising keratin proteins.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: July 11, 2017
    Assignee: KeraNetics, LLC
    Inventors: Luke Burnett, Elizabeth Kneller, Seth Tomblyn
  • Patent number: 9695226
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 4, 2017
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Patent number: 9694081
    Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: July 4, 2017
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Jason Alan Burdick, Robert C. Gorman, Joseph H. Gorman, III, Brendan Patrick Purcell
  • Patent number: 9696321
    Abstract: The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: July 4, 2017
    Assignee: National University Corporation Okayama University
    Inventors: Kosuke Kuroda, Hiroshi Morimatsu, Hidenori Wake, Shuji Mori, Masahiro Nishibori, Hideo Takahashi, Keyue Liu, Kiyoshi Teshigawara, Masakiyo Sakaguchi
  • Patent number: 9688723
    Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides and polypeptides, which may act as transporter molecules that specifically recognize proteoglycans, in particular, chondroitin-4-sulfate (C4S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C4S expressing cells in vitro and in vivo.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: June 27, 2017
    Assignee: PHI PHARMA SA
    Inventors: Christophe Bonny, Fabrice Chenaux
  • Patent number: 9688724
    Abstract: The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 27, 2017
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 9682168
    Abstract: The disclosed subject matter can provide a nanotube-reinforced polymer composite material comprising a plurality of nanotubes, each nanotube being formed of a plurality of cyclic peptide molecules, disposed within a polymer matrix, such as a biodegradable polymer matrix. A cyclic polymer, such as a cyclic 8-mer, composed of amino acid residues of alternating absolute configurations (D/L, R/S), can self-assemble into nanotubes useful for preparation of the composite polymer material of the invention. For example, the cyclic peptide (QL)4, wherein the glutamine and leucine residues are of opposite absolute configuration, self-assembles into nanotubes, which when formed into a reinforced polymer composite including poly(caprolactone), provides a biocompatible material of greater tensile strength and Young's modulus compared to the poly(caprolactone) material alone. The nanotubes can be prepared by a vapor equilibration technique or by a solvent-nonsolvent precipitation technique.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: June 20, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Neel Satish Joshi, Daniel James Rubin
  • Patent number: 9682098
    Abstract: The invention relates to a compound suited as entity carrier, having the general formula (I) wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier system, a kit comprising such compounds and methods for gene silencing and anti-cancer treatment.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: June 20, 2017
    Assignees: Ramot at Tel-Aviv University Ltd., Freie Universitaet Berlin
    Inventors: Rainer Haag, Wiebke Fischer, Abdul Mohiuddin Quadir, Ronit Satchi-Fainaro, Paula Ofek
  • Patent number: 9675675
    Abstract: A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 13, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Ying Zhang, Percy T. Fenn, Peter R. Johnson
  • Patent number: 9676702
    Abstract: The invention relates to novel methods for synthesizing a synthon for ?,?-dihydroxyisoleucine 1 (CAS No. 55399-94-5] as building block for the synthesis of amatoxins, and for novel methods for synthesizing amatoxins using such building block.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 13, 2017
    Assignee: Heidelberg Pharma GmbH
    Inventors: Christian Lutz, Christoph Mueller, Werner Simon